{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:21:15Z","timestamp":1791498075268,"version":"4.3.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Intraventricular compartmental radioimmunotherapy (cRIT) with 131-I-omburtamab is a potential therapy for recurrent primary brain tumors that can seed the thecal space. These patients often previously received external beam radiotherapy (EBRT) to a portion or full craniospinal axis (CSI) as part of upfront therapy. Little is known regarding outcomes after re-irradiation as part of multimodality therapy including cRIT. This study evaluates predictors of response, patterns of failure, and radiologic events after cRIT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with recurrent medulloblastoma or ependymoma who received 131-I-omburtamab on a prospective clinical trial were included. Extent of disease at cRIT initiation (no evidence of disease [NED] vs measurable disease [MD]) was assessed as associated with progression-free (PFS) and overall survival (OS) by Kaplan\u2013Meier analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All 27 patients (20 medulloblastoma, 7 ependymoma) had EBRT preceding cRIT: most (22, 81%) included CSI (median dose 2340\u00a0cGy, boost to 5400\u00a0cGy). Twelve (44%) also received EBRT at relapse as bridging to cRIT. There were no cases of radionecrosis. At cRIT initiation, 11 (55%) medulloblastoma and 3 (43%) ependymoma patients were NED, associated with improved PFS (p\u2009=\u20090.002) and OS (p\u2009=\u20090.048) in medulloblastoma. Most relapses were multifocal. With medium follow-up of 3.0\u00a0years (95% confidence interval, 1.8\u20137.4), 6 patients remain alive with NED.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>For patients with medulloblastoma, remission at time of cRIT was associated with significantly improved survival outcomes. Relapses are often multifocal, particularly in the setting of measurable disease at cRIT initiation. EBRT is a promising tool to achieve NED status at cRIT initiation, with no cases of radiation necrosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11060-022-04235-w","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T14:02:50Z","timestamp":1677592970000},"page":"69-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma"],"prefix":"10.1007","volume":"162","author":[{"given":"Kathryn R.","family":"Tringale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne L.","family":"Wolden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Karajannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Rosenblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal K.","family":"Benhamida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Kong","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Souweidane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Pandit-Taskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pat B.","family":"Zanzonico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Humm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"4235_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3109\/0284186X.2013.862596","volume":"53","author":"K Christopherson","year":"2014","unstructured":"Christopherson K, Rotondo R, Bradley J et al (2014) Late toxicity following craniospinal radiation for early-stage medulloblastoma. Acta Oncol (Madr) 53:471\u2013480","journal-title":"Acta Oncol (Madr)"},{"issue":"255","key":"4235_CR2","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1007\/s00405-014-3013-7","volume":"271","author":"N Oker","year":"2014","unstructured":"Oker N, Lang P, Bresson D et al (2014) Radionecrosis of the frontal lobe as a consequence of malignant ethomid tumor management: incidence, diagnosis, risk factors, prevention, and management. Eur Arch Oto-Rhino-Laryngol 271(255):3223\u20133232","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"key":"4235_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-009-0038-7","author":"K Kramer","year":"2010","unstructured":"Kramer K, Kushner BH, Modak S et al (2010) Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol. https:\/\/doi.org\/10.1007\/s11060-009-0038-7","journal-title":"J Neurooncol"},{"issue":"34","key":"4235_CR4","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1200\/JCO.2007.11.1807","volume":"25","author":"K Kramer","year":"2007","unstructured":"Kramer K, Humm J, Souweidane M et al (2007) Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using Intra-Ommaya 131-I-3F8. J Clin Oncol 25(34):5465\u20135470","journal-title":"J Clin Oncol"},{"key":"4235_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01383-4","author":"K Kramer","year":"2022","unstructured":"Kramer K, Pandit-Taskar N, Kushner B et al (2022) Phase 1 study of intraventricular 131-I-omburtamab targeting B7H3(CD276)-expressing CNS malignancies. J Hematol Oncol. https:\/\/doi.org\/10.1186\/s13045-022-01383-4","journal-title":"J Hematol Oncol."},{"key":"4235_CR6","doi-asserted-by":"publisher","first-page":"e26754","DOI":"10.1002\/pbc.26754","volume":"65","author":"K Kramer","year":"2018","unstructured":"Kramer K, Pandit-Taskar N, Humm J et al (2018) A phase II study of radioimmunotherapy with intraventricular 131-I-3F8 for medulloblastoma. Pediatr Blood Cancer. 65:e26754","journal-title":"Pediatr Blood Cancer."},{"key":"4235_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-015-1788-z","author":"K Kramer","year":"2015","unstructured":"Kramer K, Pandit-Taskar N, Zanzonico P et al (2015) Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy. J Neurooncol. https:\/\/doi.org\/10.1007\/s11060-015-1788-z","journal-title":"J Neurooncol"},{"key":"4235_CR8","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0. DCTD, NCI, NIH, DHHS Cancer Therapy Evaluation Program NIH publication #09\u20137473"},{"issue":"9","key":"4235_CR9","first-page":"1188","volume":"17","author":"B Ellingson","year":"2015","unstructured":"Ellingson B, Bendszus M, Boxerman J, Barboriak D, Al E (2015) Consensus recommendations for a standardized Brain tumor imaging protocol in clinical trials. Neuro Oncol 17(9):1188\u20131198","journal-title":"Neuro Oncol"},{"issue":"11","key":"4235_CR10","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"P Wen","year":"2010","unstructured":"Wen P, Macdonald D, Reardon D, Al E (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963\u20131972","journal-title":"J Clin Oncol"},{"issue":"6","key":"4235_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1470-2045(11)70057-2","volume":"12","author":"M van den Bent","year":"2011","unstructured":"van den Bent M, Wefel J, Schiff D, Al E (2011) Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12(6):583\u2013593","journal-title":"Lancet Oncol"},{"issue":"4","key":"4235_CR12","first-page":"484","volume":"19","author":"M Chamberlain","year":"2017","unstructured":"Chamberlain M, Junck L, Brandsma D, Al E (2017) Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol 19(4):484\u2013492","journal-title":"Neuro Oncol"},{"issue":"2","key":"4235_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.bbmt.2015.08.035","volume":"22","author":"A Cowan","year":"2015","unstructured":"Cowan A, Stevenson P, Cassaday R, Graf S, Fromm J (2015) Pretransplant minimal residual disease predicts survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation in complete remission. Biol Blood Marrow Transpl 22(2):380\u2013385","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"4235_CR14","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3324\/haematol.2016.159343","volume":"102","author":"S Buckley","year":"2017","unstructured":"Buckley S, Wood B, Othus M, Hoirgan C, Ustun C, Linden M (2017) Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica 102(5):865\u2013873","journal-title":"Haematologica"},{"issue":"3","key":"4235_CR15","doi-asserted-by":"publisher","first-page":"S170","DOI":"10.1016\/j.bbmt.2018.12.309","volume":"25","author":"K Curran","year":"2019","unstructured":"Curran K, Margossian S, Kernan N et al (2019) Conditioning prior to CAR T cells predicts response and survival in pediatric\/young adult relapse\/refractory (R\/R) B-ALL. Biol Blood Marrow Transplant 25(3):S170","journal-title":"Biol Blood Marrow Transplant"},{"key":"4235_CR16","unstructured":"Dalton M (2019) Debate About Brainstem Injury Risk After Proton and Photon Therapies in Pediatric Brain Tumors. ASCO Daily News. https:\/\/dailynews.ascopubs.org\/do\/debate-brainstem-injury-risk-after-proton-and-photon-therapies-pediatric-braintumors"},{"key":"4235_CR17","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ijrobp.2017.11.026","volume":"100","author":"M Gentile","year":"2018","unstructured":"Gentile M, Yeap B, Paganetti H et al (2018) Brainstem injury in pediatric patients with posterior fossa tumors treated with proton beam therapy and associated dosimetric factors. Int J Radiat Oncol 100:719\u2013729","journal-title":"Int J Radiat Oncol"},{"key":"4235_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijrobp.2018.01.013","volume":"101","author":"D Haas-Koggan","year":"2018","unstructured":"Haas-Koggan D, Indelicato D, Paganetti H (2018) National cancer institute workshop on proton therapy for children: considerations regarding brainstem injury. Int J Radiat Oncol 101:152\u2013168","journal-title":"Int J Radiat Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04235-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-022-04235-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04235-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T08:11:29Z","timestamp":1679991089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-022-04235-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["4235"],"URL":"https:\/\/doi.org\/10.1007\/s11060-022-04235-w","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"assertion":[{"value":"27 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both Memorial Sloan Kettering Cancer Center (MSK) and Dr. Cheung have financial interest in Y-mAbs, Abpro-Labs and Eureka Therapeutics. Dr. Cheung also reports receiving commercial research grants from Y-mabs Therapeutics and Abpro-Labs Inc. Dr. Cheung was named as inventor on multiple patents filed by MSK, including naxitamab and omburtamab licensed to Ymabs Therapeutics, and others licensed to Biotec Pharmacon, and Abpro-labs. Dr. Cheung is a SAB member for Eureka Therapeutics. Dr. Modak and Dr. Kramer reports consulting and equity in Ymabs, Therapeutics Inc. Omburtamab was licensed to Y-mAbs Therapeutics in 2015. Dr. Karajannis reports grants from Y-mAbs Therapeutics, Inc. (research support) and personal fees from Bayer AG, AstraZeneca, Inc., QED Therapeutics, Inc., CereXis, Inc., Recursion, Inc., Cardinal Health and Medscape (Medical Advisory Board and\/or consultant).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}